Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

IMUXBullishCorporate Developmentsnews

High materiality8/10

Stifel Starts Coverage on Immunic with Buy Rating and Price Target of $2.50

Apr 17, 2026, 2:41 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Stifel's Buy rating and favorable price target provide positive momentum for IMUX. Historical examples show that analyst upgrades can lead to upward price movements, especially when clinical data is forthcoming.

AI summary

What happened, with direct paths to the underlying reporting

Stifel has initiated coverage on Immunic (IMUX) with a Buy rating and a price target of $2.50, citing its lead candidate, VidoCa, as a promising treatment for multiple sclerosis. The potential for improved safety profiles may help VidoCa capture market share amid existing competitive pressures, with critical data expected by late 2026 and regulatory submission in 2027.

Stifel initiated coverage on IMUX with a Buy rating and $2.50 price target.
IMUX's lead program, VidoCa, is in phase 3 trials for MS.
Top-line data from trials is expected by late 2026.
VidoCa may offer improved safety profiles over existing MS therapies.
The crowded MS market poses risks but also historical opportunities.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Stifel Starts Coverage on Immunic with Buy Rating and Price Target of $2.50

Immunic Stock Jumps After Pricing $400 Million Private Placement